Since 2022, the shortage of GLP-1 drugs has allowed increased compounding, bypassing usual restrictions. Partners Avia Dunn and Maya Florence and of counsel Rachel Turow explore what compounding is, why compounders are allowed to make GLP-1s and what may happen when approved GLP-1s are no longer in shortage.
The Future of GLP-1 Policy After Drug Shortage Ends
Law360